Jimandin (Sitagliptin)

Sitagliptin works by selectively blocking the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prolongs the action of incretin hormones, which increase insulin release and decrease glucagon production in a glucose‑dependent manner, thereby improving overall glycemic control.

The appropriate dose of Jimandin is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Jimandin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jimandin (sitagliptin) belongs to the DPP‑4 inhibitor class, offering glucose‑dependent insulin secretion without causing weight gain, unlike some sulfonylureas. Compared with metformin, it has a different mechanism and is often added when metformin alone does not achieve target glycaemia. Choice depends on patient profile, tolerability and therapeutic goals.

Jimandin tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, direct sunlight and excessive heat. Keep out of reach of children and do not use after the expiry date printed on the label.

Jimandin is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events associated with sitagliptin include pancreatitis, severe allergic reactions such as Stevens‑Johnson syndrome, and rare cases of bullous pemphigoid. Patients should seek immediate medical attention for persistent abdominal pain, rash, or signs of an allergic reaction.

Jimandin is contraindicated in patients with a known hypersensitivity to sitagliptin or any of its excipients. Caution is advised in individuals with severe renal impairment, hepatic disease, or a history of pancreatitis. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.